PDE5A and benign prostatic hyperplasia: Increasing the NO/cGMP pathway activity by inhibiting PDE5 with inhibitors, such as tadalafil, is used in daily clinical practice for treatment of benign prostatic hyperplasia and erectile dysfunction4.